Home/Filings/4/0001610717-26-000035
4//SEC Filing

DORMAN STUART 4

Accession 0001610717-26-000035

CIK 0001676725other

Filed

Feb 1, 7:00 PM ET

Accepted

Feb 2, 8:00 PM ET

Size

5.5 KB

Accession

0001610717-26-000035

Research Summary

AI-generated summary of this filing

Updated

IDEAYA (IDYA) CCO Stuart Dorman Receives 155,000-Share Award

What Happened
Stuart Dorman, Chief Commercial Officer of IDEAYA Biosciences (IDYA), was granted 155,000 derivative shares (award) on January 30, 2026. The award was reported as acquired at $0.00, meaning no cash was paid at grant—this is a compensation award (e.g., RSUs or similar equity-based award) rather than an open‑market purchase or sale.

Key Details

  • Transaction date: 2026-01-30; Form 4 filed: 2026-02-02.
  • Grant type: Derivative award (code A); 155,000 shares acquired at $0.00 (no cash consideration).
  • Vesting (per footnote): 25% vests on the first anniversary measured from January 1, 2026 (the Vesting Commencement Date), then 1/48th of total shares vest monthly thereafter; 100% vests on the fourth anniversary.
  • Shares owned after the transaction: not specified in the provided filing summary.
  • No indication of a sale, cash exercise, gift, or tax-withholding event in this report.

Context
This is a standard equity compensation grant to an executive and does not represent an open-market buy or sell. Such awards typically align executive incentives with long-term shareholder value but do not immediately change public float or signal a near-term trading intent. The filing date (Feb 2, 2026) closely follows the transaction date (Jan 30, 2026), consistent with routine insider reporting timelines.

Insider Transaction Report

Form 4
Period: 2026-01-30
DORMAN STUART
Chief Commercial Officer
Transactions
  • Award

    Stock Option (right to buy)

    [F1]
    2026-01-30+155,000155,000 total
    Exercise: $32.19Exp: 2036-01-30Common Stock (155,000 underlying)
Footnotes (1)
  • [F1]25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Signature
/s/ Joshua Bleharski, as Attorney-in-Fact for Stuart Dorman|2026-02-02

Documents

1 file

Issuer

IDEAYA Biosciences, Inc.

CIK 0001676725

Entity typeother

Related Parties

1
  • filerCIK 0002047580

Filing Metadata

Form type
4
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 8:00 PM ET
Size
5.5 KB